Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants

Famitinib is a tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors. Here, a 3-period crossover trial investigated the effect of high-fat or low-fat food intake on the single-dose pharmacokinetic properties of oral famitinib. Twenty-four healthy Chinese participants were enrolled and received a single 25-mg dose of famitinib malate capsule following a high-fat or low-fat breakfast before dosing. Blood samples were collected before dosing (0 hour) to 192 hours after dosing, and famitinib concentrations in plasma were determined with validated liquid chromatography-tandem mass spectrometry. Compared with the fasting condition, the geometric mean ratios for low-fat/fasting were 98.6%, 107.7%, and 107.5% for maximum plasma concentration, area under the plasma concentration-time curve (AUC) over the dosing interval, and AUC from time 0 to infinity, respectively. Those for high-fat/fasting were 84.4%, 105.0%, and 105.1% for maximum plasma concentration, AUC over the dosing interval, and AUC from time 0 to infinity, respectively. There was no significant difference in adverse events between fasting and fed conditions, and no serious adverse events occurred during the trial. In conclusion, oral famitinib bioavailability is not affected by food intake, implying that patients with cancer do not need to consider dietary status when using famitinib. This is considered important for convenience and treatment compliance.

[1]  Xiaoping Cai,et al.  Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis , 2022, Pharmacology.

[2]  Ping Shi,et al.  The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects , 2022, Cancer Chemotherapy and Pharmacology.

[3]  Ting Dou,et al.  Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects , 2022, Investigational New Drugs.

[4]  Xiaoping Zhou,et al.  Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study , 2022, Journal for ImmunoTherapy of Cancer.

[5]  Yujin Lee,et al.  Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem , 2021, Scientific Reports.

[6]  L. Lou,et al.  Third‐generation EGFR inhibitor HS‐10296 in combination with famitinib, a multi‐targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR‐mutant non‐small cell lung cancer cells , 2021, Thoracic cancer.

[7]  Christine M. Madla,et al.  The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  M. Miccoli,et al.  Sunitinib in the Treatment of Thyroid Cancer. , 2019, Current medicinal chemistry.

[9]  Qingmei He,et al.  Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study , 2018, Cancer communications.

[10]  Xia Tao,et al.  LC-MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma. , 2018, Bioanalysis.

[11]  C. Lovly,et al.  Mechanisms of receptor tyrosine kinase activation in cancer , 2018, Molecular Cancer.

[12]  Z. Zuo,et al.  A Review of Food–Drug Interactions on Oral Drug Absorption , 2017, Drugs.

[13]  M. Ratain,et al.  Food Effect Studies for Oncology Drug Products , 2017, Clinical pharmacology and therapeutics.

[14]  Shuangbing Xu,et al.  Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation , 2015, International journal of radiation biology.

[15]  Jian Zhang,et al.  Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer , 2014, Cancer Chemotherapy and Pharmacology.

[16]  Xiaoyan Chen,et al.  Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib , 2013, Cancer Chemotherapy and Pharmacology.

[17]  Xiaoyan Chen,et al.  Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients , 2013, British journal of pharmacology.

[18]  D. Greenblatt,et al.  Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs , 2008, Journal of clinical pharmacology.

[19]  D. Greenblatt,et al.  The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates , 2005, Clinical Pharmacokinetics.

[20]  H. Zhou,et al.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. , 2000, British journal of clinical pharmacology.